Brookline Capital Downgrades POINT Biopharma Global to Hold, Lowers Price Target to $12.5
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Kemp Dolliver downgraded POINT Biopharma Global (PNT) from Buy to Hold and reduced the price target from $27 to $12.5.
December 21, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
POINT Biopharma Global was downgraded by Brookline Capital from Buy to Hold with a significant reduction in price target from $27 to $12.5.
The downgrade from Buy to Hold suggests that Brookline Capital no longer sees the same growth potential or value in PNT as before. The halving of the price target is a significant negative revision, indicating a bearish view on the stock's value and potential performance. This is likely to negatively influence investor sentiment and could lead to a short-term decline in PNT's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100